Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4756568 | 0.78 | HSD11B1 (0.48) | HSD11B1SIGMAR1 | |
| SCHEMBL4756096 | 0.76 | RIPK1 (0.51) | — | |
| SCHEMBL4810452 | 0.75 | HSD11B1 (0.61) | HSD11B1SIGMAR1 | |
| SCHEMBL4704893 | 0.74 | DRD1 (0.44) | — | |
| SCHEMBL4704570 | 0.71 | HSD11B1 (0.45) | HSD11B1 | |
| SCHEMBL4759099 | 0.71 | ALDH1A1 (0.47) | HSD11B1 | |
| SCHEMBL3143393 | 0.71 | POLB (0.55) | — | |
| SCHEMBL3139520 | 0.71 | POLB (0.55) | — | |
| SCHEMBL4705468 | 0.70 | MAPT (0.37) | HSD11B1 | |
| SCHEMBL4705470 | 0.69 | RUVBL1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-01-12 | — | — | US | claimed |
| EP-1758582-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1758582-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006002349-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885SIGMAR1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.